Current Report Filing (8-k)
April 30 2019 - 9:36AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
April 30, 2019
Citius Pharmaceuticals, Inc.
(Exact name of registrant as specified
in its charter)
Nevada
(State or other jurisdiction of incorporation)
333-206903
|
|
27-3425913
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
|
|
|
11 Commerce Drive, 1st
Floor, Cranford, NJ
|
|
07016
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including area
code
(908) 967-6677
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. Other Events.
On April 30, 2019, we issued a press release
to report on data regarding the clinical efficacy of Mino-Lok against various pathogens encountered in colonized catheters that
cause either central line associated bloodstream infection or catheter related bloodstream infection.
A copy of the press release is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CITIUS PHARMACEUTICALS, INC.
|
|
|
Date: April 30, 2019
|
By:
|
/s/ Myron Holubiak
|
|
|
Myron
Holubiak
President and Chief Executive Officer
|
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Apr 2023 to Apr 2024